TACL
Therapeutic Advances in Childhood Leukemia & Lymphoma
Log in
T2020-004 Trametinib
Protocol Opened:
9/21/2023
Study Contacts
Protocol Chair & Protocol Biology Chair:
Elliot Stieglitz, MD
Protocol Vice-Chair: Mignon Loh, MD
CURRENT STUDY DOCUMENTS
T2020-004 Trametinib Study Protocol Amendment #1 Tracked
T2020-004 Trametinib Study Protocol Amendment #1 Clean
T2020-004 Trametinib Protocol Amendment #1 Master Consent
v. 11.5.2024
T2020-004 Trametinib Protocol Amendment #1 Master Assent
T2020-004 Trametinib Protocol Amendment #1 Master Addendum to the Consent
T2020-004 Trametinib Eligibility Worksheet
T2020-004 Enrollment Procedures Video Training
T2020-004
Trametinib
Research Monitoring Plan
T2020-004
Trametinib
Investigator Team Training Link
T2020-004
Trametinib
Investigator Training - Slides
T2020-004 Trametinib Investigator Training Log Template
T2020-004
Trametinib
Investigator Acknowledgment version 14FEB2024
T2020-004
Trametinib
Investigator Brochure version 16
T2020-004
Trametinib
Investigator Financial Disclosure Form
T2020-004
Trametinib
FDA Form 1572 Template
T2020-004 Trametinib TACL Delegation of Authority Template
T2020-004 Continuing Renewal 2024-2025
PREVIOUS STUDY DOCUMENTS
T2020-004 Trametinib Original Protocol
T2020-004 Trametinib Investigator Acknowledgment version 2
9AUG2023
Adverse Events, SAE/DLT and AE Reporting Manual
Study Sample Form & Lab Manual
Roadmaps & Weekly Reports
Enrollment & Eligibility
Drug Logistics & Pharmacy Manual
eCRF Completion Guidelines
Data Safety & Progress Reports
External SUSARs from Novartis
FAQ